난소암 세포주에서 클러스터린의 항암제 결합과 항암제 내성의 연관성 = The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells

다국어 초록 (Multilingual Abstract)

Objective: The purpose of this study was to determine the mechanism of action of clusterin-known as a chemo-resistance protein-by analyzing its binding with chemotherapeutic agents and elucidating its relation with drug resistance. Methods: Chemotherapeutic agents were diluted with coating buffer and coated onto 96 well plates. We then had these agents cross-react with purified clusterin and wash the wells to remove residual clusterin. We quantified the amount of clusterin with optical density (OD) measured by binding peroxidase-conjugated secondary antibody associated with mouse monoclonal clusterin antibody. To determine if anticancer drug-clusterin binding is related to chemotherapeutic agent resistance, we compared survival rates in the SKOV-3 cell line, which rarely secretes clusterin. We compared a group of SKOV-3 cells treated with a chemotherapeutic agent and a group treated with both the agent and clusterin, by means of XTT. Results: In binding tests using ELISA OD, ratios of paclitaxel, cisplatin, carboplatin, topotecan, Adriamycin, etoposide, and 5-fluoruracil (5-FU) were 2.34, 2.40, 0.52, 2.44, 1.602, 1.14, and 1.13, respectively. Topotecan, cisplatin, and paclitaxel showed relatively higher binding. In addition, when these drugs were treated with clusterin in SKOV-3 cells, anticancer resistance increased (P<0.05). Conclusions: The anticancer drug resistance endowed by clusterin is considered to be related to its binding with chemotherapeutic agents.

참고문헌 (Reference)

1 박동춘, "난소암에서 Paclitaxel의 내성에 관여하는 Clusterin" 대한산부인과학회 48 (48): 2313-2320, 2005

2 Scaffidi C, "Two CD95 (APO-1/Fas) signaling pathways" 17 : 1675-1687, 1998

3 Fink D, "The role of DNA mismatch repair in drug resistance" 4 : 1-6, 1998

4 Miyake H, "The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer" 15 : 507-517, 2006

5 Raisova M, "Resistance to CD95/ Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release" 473 : 27-32, 2000

6 Sensibar JA, "Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2(clusterin)" 55 : 2431-2437, 1995

7 Zellweger T, "Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model" 92 : 463-469, 2003

8 Miyake H, "Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence" 59 : 150-240, 2002

9 Redondo M, "Overexpression of clusterin in human breast carcinoma" 157 : 393-399, 2000

10 Atalay C, "Multidrug resistance in locally advanced breast cancer" 27 : 309-318, 2006

11 Itamochi H, "Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma" 99 : 653-658, 2008

12 Ugurel S, "Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma" 82 : 727-736, 1999

13 Zhang K, "Glutathionerelated mechanisms in cellular resistance to anticancer drugs" 12 : 871-882, 1998

14 Kurahashi T, "Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension" 96 : 895-899, 2005

15 Yamanaka K, "Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model" 13 : 885-890, 2005

16 Reed JC, "Dysregulation of apoptosis in cancer" 17 : 2941-2953, 1999

17 Petty R, "Drug resistance in ovarian cancer - the role of p53" 4 : 97-102, 1998

18 Wilson MR, "Clusterin is a secreted mammalian chaperone" 25 : 95-98, 2000

19 Humphreys DT, "Clusterin has Chaperone-Like Activity Similar to that of Small Heat-Shock Proteins" 274 : 6875-6881, 1999

20 Gottesman MM, "Biochemistry of multidrug resistance mediated by the multidrug transporter" 62 : 385-427, 1993

21 Zou H, "Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome cdependent activation of caspase-3" 90 : 405-413, 1997

22 Beck WT, "Altered DNA topoisomerase II in multidrug resistance" 11 : 115-119, 1993